Advertisement
UK markets close in 1 hour 36 minutes
  • FTSE 100

    7,967.99
    +36.01 (+0.45%)
     
  • FTSE 250

    19,893.33
    +82.67 (+0.42%)
     
  • AIM

    743.69
    +1.58 (+0.21%)
     
  • GBP/EUR

    1.1697
    +0.0028 (+0.24%)
     
  • GBP/USD

    1.2635
    -0.0003 (-0.02%)
     
  • Bitcoin GBP

    56,547.66
    +1,329.54 (+2.41%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,253.30
    +4.81 (+0.09%)
     
  • DOW

    39,765.65
    +5.57 (+0.01%)
     
  • CRUDE OIL

    82.38
    +1.03 (+1.27%)
     
  • GOLD FUTURES

    2,232.10
    +19.40 (+0.88%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,494.93
    +17.84 (+0.10%)
     
  • CAC 40

    8,215.80
    +10.99 (+0.13%)
     

Athenex Third Quarter 2022 Earnings: Beats Expectations

Athenex (NASDAQ:ATNX) Third Quarter 2022 Results

Key Financial Results

  • Revenue: US$33.5m (up 6.7% from 3Q 2021).

  • Net loss: US$19.4m (loss narrowed by 43% from 3Q 2021).

  • US$0.14 loss per share (improved from US$0.31 loss in 3Q 2021).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Athenex Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) also surpassed analyst estimates by 6.7%.

Looking ahead, revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Athenex is showing 5 warning signs in our investment analysis and 2 of those are potentially serious...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here